Brief: Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results And Recent Corporate Highlights
04/05/2023 12:14
Aldeyra Therapeutics Inc ALDX.O :
* ALDEYRA THERAPEUTICS REPORTS FIRST-QUARTER 2023 FINANCIAL
RESULTS AND RECENT CORPORATE HIGHLIGHTS
* CASH AND CASH EQUIVALENTS OF $165.0 MILLION AS OF MARCH
31, 2023
* ALDEYRA THERAPEUTICS - BELIEVES EXISTING CASH AND CASH
EQUIVALENTS WILL BE SUFFICIENT TO FUND CURRENTLY PROJECTED
OPERATING EXPENSES INTO H2 OF 2024
* QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.27
* Q1 EARNINGS PER SHARE VIEW $-0.29 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw96Y3Lga
Further company coverage: ALDX.O
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug